Results 11 to 20 of about 81,306 (284)

Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation

Scientific Reports, 2017
This study evaluated the impact of calcium and magnesium on the in vitro degradation and in vivo clearance of oxaliplatin. Intact oxaliplatin and Pt(DACH)Cl2 were measured in incubation solutions by HPLC-UV.
Catherine H. Han, Prashannata Khwaounjoo, Andrew G. Hill, Gordon M. Miskelly, Mark J. McKeage   +4 more
doaj   +2 more sources

Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect

Journal of Pharmacological Sciences, 2019
Oxaliplatin induces severe peripheral neuropathy. The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models.
Takehiro Kawashiri, Shiori Shimizu, Nao Shigematsu, Daisuke Kobayashi, Takao Shimazoe   +4 more
doaj   +2 more sources

Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: differences between oxaliplatin-naive versus oxaliplatin-pretreated patients

ESMO Gastrointestinal Oncology
Background: Oxaliplatin-based hepatic arterial infusions (HAI) combined with intravenous therapy is a therapeutic option for colorectal cancer with liver-only metastasis, notably in the palliative setting, either initially or after failure of systemic ...
E. El Rawadi, B. Bonnet, L. Pierotti, V. Boige, L. Tselikas, C. Smolenschi, M. Valéry, T. Pudlarz, A. Fuerea, T. De Baere, A. Tarabay, M. Gelli, E. Fernandez-de-Sevilla, D. Malka, A. Hollebecque, M. Ducreux, A. Boilève   +16 more
doaj   +2 more sources

Comparison of click-capable oxaliplatin and cisplatin derivatives to better understand Pt(II)-induced nucleolar stress [PDF]

, 2023
Pt(II) chemotherapeutic compounds have been used as predominant anticancer drugs for nearly fifty years. Currently there are three FDA-approved chemotherapeutic Pt(II) compounds: cisplatin, carboplatin, and oxaliplatin.
Paul, O\u27Dowd, Hannah, Pigg, Darren, Griffith, Katelyn, Alley, Andres, Guerrero, Victoria, DeRose   +5 more
core   +2 more sources

Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon [PDF]

, 2018
Oxaliplatin is a platinum-based chemotherapeutic used for cancer treatment. Its use associates with peripheral neuropathies and chronic gastrointestinal side-effects.
Rhian Stavely (5374472), Samy Sakkal (799080), Shakuntla Gondalia (18923350), Vasso Apostolopoulos (20994), Enzo Palombo (18926020), Monica Prakash (3914885), Rachel M. McQuade (5374466), Sarah Fraser (5106503), Kulmira Nurgali (799081), Vanesa Stojanovska (4667026)   +9 more
core   +3 more sources

Oxaliplatin in practice [PDF]

British Journal of Cancer, 1998
Oxaliplatin, a new third-generation platinum complex, is active in the treatment of colorectal and advanced ovarian cancers, both as monotherapy and in combination therapy. It has demonstrated a very good safety profile, characterized by low haematotoxicity, and moderate and manageable gastrointestinal toxicity.
openaire   +2 more sources

Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review [PDF]

, 2007
Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
Pavlakis, Nick, Ross Davey, Davey, Ross, Nick Pavlakis, Britta Stordal, Stordal, Britta, Stordal, B., Pavlakis, N., Davey, R.   +8 more
core   +2 more sources

Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]

, 2009
Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
Pavlakis, Nick, Ross Davey, Davey, Ross, Nick Pavlakis, Britta Stordal, Stordal, Britta   +5 more
core   +2 more sources

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation [PDF]

, 2006
Objectives: To assess the clinical and cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/ leucovorin (5-FU/LV), and capecitabine monotherapy (within their licensed indications), as adjuvant therapies in the treatment of ...
Tappenden, P., P Tappenden, Sutcliffe, P., P Sutcliffe, S Paisley, S Eggington, Sutcliffe, P. (Paul), Paisley, S., Eggington, S., A Pandor, Egginton, S., Pandor, A.   +11 more
core   +1 more source

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]

, 2013
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Erik Engel, Engel, Erik, Jürgen Dunst, Florian Würschmidt, Kathrin Dellas, Arnold, Dirk, Dirk Arnold, Michael Richter, Richter, Michael, Rödel, Claus, Thomas Reese, Höhler, Thomas, Thomas Höhler, Claus Rödel, Dellas, Kathrin, Reese, Thomas, Wagner, Wolfgang, Dunst, Jürgen, Würschmidt, Florian, Wolfgang Wagner   +19 more
core   +1 more source